Can GLP-1 drugs for obesity and diabetes, like Ozempic and Wegovy, help change the food industry? Consumers on these drugs experience a decline in their appetite and their appeal for sugary snacks filled with fats and sodium. Could this inspire consumer products companies to create healthier snacks?